Allspring Global Investments Holdings LLC Trims Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Allspring Global Investments Holdings LLC decreased its position in Ascendis Pharma A/S (NASDAQ:ASND) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 152,738 shares of the biotechnology company’s stock after selling 8,672 shares during the period. Allspring Global Investments Holdings LLC owned 0.25% of Ascendis Pharma A/S worth $21,077,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in ASND. Wilmington Savings Fund Society FSB acquired a new stake in Ascendis Pharma A/S during the third quarter worth $30,000. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth $60,000. Blue Trust Inc. increased its position in shares of Ascendis Pharma A/S by 540.5% during the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company’s stock worth $76,000 after purchasing an additional 427 shares during the last quarter. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Signaturefd LLC lifted its position in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter.

Ascendis Pharma A/S Stock Up 1.1 %

ASND stock opened at $144.08 on Friday. The stock has a market cap of $8.74 billion, a price-to-earnings ratio of -17.83 and a beta of 0.64. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The business has a 50 day moving average price of $132.41 and a 200 day moving average price of $132.35.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday. Stifel Nicolaus boosted their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, TD Cowen dropped their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $193.43.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.